● Recruiting

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

Condition: Transthyretin Amyloidosis · ATTR-CM · ATTRv-PN · Sponsor: AstraZeneca

PhaseN/A

Planned participants1850

Who can joinAll sexes, 18 Years to 130 Years

Healthy volunteersNo

About this study

The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.

This description comes directly from the study's public registry record.

Talk to the study team

AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com

Always discuss trial participation with your own doctor first.

Locations (82)

Research Site	La Jolla, California, United States	Recruiting
Research Site	Los Angeles, California, United States	Recruiting
Research Site	San Francisco, California, United States	Recruiting
Research Site	San Francisco, California, United States	Recruiting
Research Site	New Haven, Connecticut, United States	Recruiting
Research Site	Washington D.C., District of Columbia, United States	Recruiting
Research Site	Chicago, Illinois, United States	Recruiting
Research Site	Indianapolis, Indiana, United States	Recruiting
Research Site	Boston, Massachusetts, United States	Recruiting
Research Site	Boston, Massachusetts, United States	Not Yet Recruiting
Research Site	Boston, Massachusetts, United States	Recruiting
Research Site	Rochester, Minnesota, United States	Recruiting

+ 70 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06465810